Operating cash flow was 2.32x net income in Q3 2026 but dropped to 0.46x in Q1 2026 as working capital absorbed $16.3M, while FCF margin averaged roughly 6 to 7 percent over recent trailing quarters, suggesting cash conversion remains positive but volatile.
Guardian Pharmacy Services, Inc. (GRDN) cash flow statement — 8-year operating, investing & financing cash flows
| Metric | TTM | Dec'25 | Dec'24 | Dec'23 | Dec'22 | Dec'21 | Dec'20 | Dec'19 | Dec'18 |
|---|
| Cash from Operations | 114.06M | 100.29M | 57.96M | 70.82M | 48.52M | 58.5M | 52.61M | 56.16M | 43.67M |
| Operating CF Margin % | - | 6.92% | 4.72% | 6.77% | 5.34% | 7.39% | 7.15% | 8.04% | 7.27% |
| Operating CF Growth % | 94.01% | 73.04% | -18.16% | 45.95% | -17.05% | 11.19% | -6.32% | 28.59% | - |
| Net Income | 74.77M | 49.22M | -71.03M | 37.72M | 49.66M | 28.33M | 29.66M | 31.37M | 23.27M |
| Depreciation & Amortization | 23.46M | 22.34M | 19.77M | 18.23M | 16.56M | 16.53M | 17.26M | 15.85M | 13.13M |
| Stock-Based Compensation | 8.61M | 13.85M | 131.49M | -6.09M | -3.38M | 13.03M | 3.21M | 1.93M | 5.98M |
| Deferred Taxes | 1.95M | 3.07M | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Cash Items | 5.96M | 5.43M | 7.14M | 5.35M | 4.4M | 2.08M | 3.58M | 5.67M | 2.95M |
| Working Capital Changes | -1.96M | 6.38M | -29.41M | 15.6M | -18.72M | -1.47M | -1.09M | 1.34M | -1.66M |
| Change in Receivables | -6.73M | -8.55M | -25.48M | -14.3M | -16.79M | -7.71M | 3.58M | -11.13M | -8.79M |
| Change in Inventory | -8.29M | -877K | -1.15M | 4.43M | -8.12M | -240K | 379K | -3.05M | 475K |
| Change in Payables | 4.8M | 16.4M | 13.23M | 6.29M | 13.37M | 9.78M | -1.95M | 7.91M | 9.05M |
| Cash from Investing | -24.67M | -32.26M | -30.41M | -13.44M | -17.9M | -13.15M | -12.18M | -16.59M | -20.75M |
| Capital Expenditures | -17.89M | -19.58M | -16.37M | -14.56M | -16.77M | -9.28M | -8.34M | -14.54M | -10.01M |
| CapEx % of Revenue | 1.23% | 1.35% | 1.33% | 1.39% | 1.85% | 1.17% | 1.13% | 2.08% | 1.67% |
| Acquisitions | -3.14M | 0 | -14.71M | -985K | -2M | -4.4M | -4.38M | -2.07M | -10.68M |
| Investments | - | - | - | - | - | - | - | - | - |
| Other Investing | -3.64M | -12.68M | 671K | 2.1M | 874K | 535K | 545K | 16K | -57K |
| Cash from Financing | -6.22M | -7.07M | -23.64M | -57.23M | -45.03M | -36.79M | -34.26M | -41.55M | -21.07M |
| Debt Issued (Net) | 8K | -4.98M | -36.48M | -2.89M | -2.8M | -6.1M | -13.37M | 2.3M | 16.03M |
| Equity Issued (Net) | 0 | -1.59M | 64.61M | 0 | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | -35.75M | -38.42M | -30.8M | -17.36M | -10.82M | -34.32M | -27.99M |
| Share Repurchases | -30.28M | -29.04M | -55.18M | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Financing | -6.23M | -497K | -16.02M | -15.92M | -11.42M | -13.34M | -10.07M | -9.52M | -9.11M |
| Net Change in Cash | 83.17M | 60.96M | 3.91M | 145K | -14.4M | 8.56M | 6.17M | -1.98M | 1.85M |
| Free Cash Flow | 96.17M | 80.71M | 41.59M | 56.26M | 31.75M | 49.22M | 44.27M | 41.62M | 33.67M |
| FCF Margin % | 6.6% | 5.57% | 3.39% | 5.38% | 3.49% | 6.21% | 6.02% | 5.96% | 5.61% |
| FCF Growth % | 41.06% | 94.05% | -26.08% | 77.2% | -35.48% | 11.17% | 6.36% | 23.63% | - |
| FCF per Share | 1.50 | 1.28 | 0.67 | 0.92 | 0.52 | 0.81 | 0.73 | 0.68 | 0.55 |
| FCF Conversion (FCF/Net Income) | 1.29x | 2.04x | -0.66x | 2.96x | 1.37x | 3.59x | 2.64x | 2.58x | 2.98x |
| Interest Paid | 590K | 650K | 3.12M | 2.78M | 1.78M | 1.52M | 2.08M | 2.25M | 1.83M |
| Taxes Paid | 24.65M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Quick answers to the most common questions about buying GRDN stock.
Guardian Pharmacy Services, Inc. (GRDN) generated $100.3M in net cash from operating activities in 2025. This reflects the cash generated directly from core business operations.
Guardian Pharmacy Services, Inc. (GRDN) generated $80.7M in free cash flow in 2025. Free cash flow is the cash left over after capital expenditures, which can be used to pay dividends, repurchase shares, or pay down debt.
Guardian Pharmacy Services, Inc. (GRDN) spent $19.6M on capital expenditures in 2025. CapEx represents the cash invested in physical assets like property, plant, and equipment to maintain or grow the business.
In 2025, Guardian Pharmacy Services, Inc. (GRDN) spent $29.0M on share repurchases. This shows the company's commitment to returning capital to its equity investors.
Key Metrics
Top Statement Risk
Working capital reversal and earnings volatility
Metrics are mathematically derived from official filings.
Operating Cash Flow Diverges From Earnings
According to reported quarterly figures, GRDN's operating cash flow exceeded net income by 2.32x in Q3 2026 and 2.87x in Q3 2025, yet this conversion ratio swung sharply, falling to 0.46x in Q1 2026 when working capital absorbed cash.
The gap between net income and operating cash flow is large and inconsistent, which suggests reported earnings alone do not explain cash generation in this business. Conversion ratios above 2x in several quarters are more likely driven by working capital timing and non-cash charges than by structurally superior earnings quality. Investors should monitor whether the sub-1x quarters reflect a recurring pattern in receivables or simply timing noise.
Free Cash Flow Margins Remain Lumpy
Based on reported figures, FCF margin ranged from 0.3% in Q1 2026 to 10.6% in Q3 2026, with the trailing quarters averaging roughly 6 to 7 percent, indicating a cash profile that is positive but highly variable.
Free cash flow has been positive in every quarter except one 2024 period, but the magnitude depends heavily on working capital swings rather than a steady expansion in operating economics. The Q1 2026 reading of roughly $1.0M shows how thin the cushion can become when receivables build. The trajectory suggests free cash flow quality hinges on sustained collection discipline rather than on demonstrated margin growth.
Asset-Light Capital Intensity Persists
Reported capital expenditure has consistently run between 1.0% and 1.8% of revenue, with quarterly CapEx between $3.0M and $5.8M, pointing to a capital-light operating model.
Low capital intensity is consistent with a service-led pharmacy model in which growth relies more on working capital and local partnerships than on heavy fixed investment. D&A near $5 to $6 million per quarter exceeds CapEx in most periods, which may indicate that the asset base is being maintained at or slightly below its depreciation rate. Investors should watch whether this underinvestment becomes a constraint as the facility footprint scales.
Working Capital Drives Cash Volatility
According to the reported cash flow statements, working capital changes swung from a $16.3M outflow in Q1 2026 to a $14.9M inflow in Q3 2026, accounting for most of the quarter-to-quarter variation in operating cash flow.
The magnitude of working capital movements relative to net income indicates that receivables, payables, or inventory timing dominates near-term cash outcomes. A large inflow in the latest quarter may partly reverse in subsequent periods, so the Q3 2026 operating cash flow should not be extrapolated without adjustment. The pattern suggests the company's cash generation depends on collection timing that warrants further investigation.
Capital Returned Sparingly Since 2024
Dividends of $16.6M and $12.3M were paid in 2024 quarters, with no dividends reported in 2025 or 2026, while acquisitions absorbed $29.0M in Q2 2025 and $30.3M in buybacks or acquisitions in Q1 2026 per reported figures.
Cash deployment has shifted from shareholder distributions toward acquisition-related spending, which is consistent with the company's bolt-on growth approach. The absence of recent dividends alongside acquisitions suggests management is prioritizing growth investment over yield. Investors should monitor whether acquired businesses generate cash returns that justify the deployed capital.
Q3 2024 Distortion Obscures Baseline
The Q3 2024 quarter, which recorded a net loss of $112.6M and a $122.4M SBC-related add-back, shows that non-cash items can dominate reported cash flow and complicate trend interpretation.
The large non-cash adjustment in Q3 2024 suggests the reported cash flow statement may require normalization before drawing long-run conclusions about free cash generation. Stock-based or other non-cash charges of this scale can make operating cash flow appear stronger or weaker than underlying economics. Investors should examine the nature of these add-backs before relying on multi-year cash averages.